(HealthDay News) — For African-Americans, sickle cell trait (SCT) is associated with increased risk of chronic kidney disease (CKD), according to a review published online November 13 in the Journal of the American Medical Association. The research was published to coincide with the American Society of Nephrology’s Kidney Week 2014, held from November 11–16 in Philadelphia.
Rakhi P. Naik, MD, MHS, from Johns Hopkins University in Baltimore, and colleagues examined the correlation between SCT and CKD and albuminuria in self-identified African-Americans. Data were collected from five large prospective studies involving 15,975 self-identified African-Americans (1,248 with SCT [carriers] and 14,727 without SCT [noncarriers]).
The researchers found that, compared with noncarriers, carriers had increased risk of CKD (odds ratio, 1.57; absolute risk difference, 7.6%); incident CKD (odds ratio, 1.79; absolute risk difference, 8.5%); and decline in estimated glomerular filtration rate (eGFR; odds ratio, 1.32; absolute risk difference, 6.1%). There was a correlation between SCT and albuminuria (odds ratio, 1.86; absolute risk difference, 12.6%).
“Among African-Americans in these cohorts, the presence of SCT was associated with an increased risk of CKD, decline in eGFR, and albuminuria, compared with noncarriers,” the authors write. “These findings suggest that SCT may be associated with the higher risk of kidney disease in African-Americans.”
Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.